Tyrosine-protein kinase ABL1 — Drug Target

All drugs that target Tyrosine-protein kinase ABL1 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Kinase Inhibitor

Marketed (3)

• Scemblix · Novartis · Oncology
  Scemblix works by blocking the ABL1 enzyme, which is involved in the growth and survival of cancer cells.
• Bosulif · Pfizer · Kinase Inhibitor · Oncology
  Bosulif works by blocking the activity of a specific enzyme called tyrosine-protein kinase ABL1, which is involved in the growth and survival of cancer cells.
• Bosulif · Pfizer · Kinase Inhibitor · Oncology
  Bosulif blocks the abnormal tyrosine kinase activity in cancer cells, inhibiting their growth and proliferation.